Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00582816 · ClinicalTrials.gov registry record · Phase 1
Haploidentical Transplant With NK Cell Infusion for Pediatric Acute Leukemia and Solid Tumors
A Phase 1 study, sponsored by University of Wisconsin, Madison.
- Terminated
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT00582816 is a Phase 1 study that was terminated before completion, run by University of Wisconsin, Madison. The registered enrollment target is 9 participants.
The verdict
NCT00582816, a Phase 1 study, was terminated before completion, sponsored by University of Wisconsin, Madison.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
This study will assess the feasibility of utilizing a reduced intensity conditioning regimen, in the setting of haploidentical transplantation, for patients with recurrent acute lymphoblastic leukemia (ALL), AML and high risk or refractory solid tumors. In addition, the feasibility and safety of administering post-transplant NK cell infusions will be evaluated. Data obtained from this study will help determine the efficacy of allogeneic HSCT in the treatment of pediatric sarcomas and add to the small body of literature utilizing haploidentical HSCT to treat acute leukemia in pediatric patients. This study will also further elucidate the role of NK cells in mediating a graft vs. tumor effect in allogeneic HSCT. The main benefit to society is that this study will explore a novel therapy for children with highly refractory cancer who are felt to be incurable with conventional approaches. If feasibility is demonstrated, and there is evidence of anti-tumor activity, then this will open up a new area of clinical research to better define the efficacy of this approach for specific childhood malignancies.
Interventions
- DEVICE Clinimacs Cell Separation System
- DRUG conditioning chemotherapy
- OTHER DLI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2008-08 |
| Est. Completion | 2015-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00582816
The ClinicalTrials.gov registry entry for NCT00582816 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Clinimacs Cell Separation System is the first listed.
NCT00582816 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00582816 about?
NCT00582816 is a clinical study titled "Haploidentical Transplant With NK Cell Infusion for Pediatric Acute Leukemia and Solid Tumors". This study will assess the feasibility of utilizing a reduced intensity conditioning regimen, in the setting of haploidentical transplantation, for patients with recurrent acute lymphoblastic leukemia (ALL), AML and high risk or refractory solid tumors. In addition, the feasibility and safety of adm...
What is the current status of trial NCT00582816?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2008-08. Estimated completion is 2015-08.
What interventions are being tested in trial NCT00582816?
The interventions under investigation include: Clinimacs Cell Separation System (DEVICE), conditioning chemotherapy (DRUG), DLI (OTHER).
Who is sponsoring clinical trial NCT00582816?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.